Last reviewed · How we verify
gefitinib combined with apatinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
gefitinib combined with apatinib (gefitinib combined with apatinib) — Qilu Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gefitinib combined with apatinib TARGET | gefitinib combined with apatinib | Qilu Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gefitinib combined with apatinib CI watch — RSS
- gefitinib combined with apatinib CI watch — Atom
- gefitinib combined with apatinib CI watch — JSON
- gefitinib combined with apatinib alone — RSS
Cite this brief
Drug Landscape (2026). gefitinib combined with apatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/gefitinib-combined-with-apatinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab